Veille Pharma
Follow
19.1K views | +3 today
Veille Pharma
Responsable des études chez VIGIEPHARMA. Mes posts n'engagent que moi. http://www.vigiepharma.fr/
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

Gilead et Boehringer Ingelheim signent un accord de licence portant sur les nouveaux inhibiteurs de l’intégrase du VIH non catalytiques

Gilead et Boehringer Ingelheim signent un accord de licence portant sur les nouveaux inhibiteurs de l’intégrase du VIH non catalytiques | Veille Pharma | Scoop.it

FOSTER CITY, Californie et INGELHEIM, Allemagne--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) et Boehringer Ingelheim ont annoncé aujourd’hui que les sociétés avaient conclu un accord de licence, en vertu duquel Boehringer Ingelheim a octroyé à Gilead les droits mondiaux exclusifs pour la recherche, le développement et la commercialisation de ses nouveaux inhibiteurs de l’intégrase de site non catalytique (NCINI) contre le VIH. Ceci comprend le principal composé, le BI 224436, qui a été évalué dans une étude de Phase 1a à doses croissantes pour en estimer la biodisponibilité et la pharmacocinétique chez des bénévoles sains.« Tandis que Gilead fera avancer les inhibiteurs de l’intégrase du VIH vers le développement clinique, nous concentrerons nos efforts de développement sur d’autres composés de notre pipeline en virologie, en particulier notre portefeuille dans le domaine de l’hépatite C. 

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

VIH: l’efficacité des nouveaux antirétroviraux confirmée chez les patients en échec thérapeutique

VIH: l’efficacité des nouveaux antirétroviraux confirmée chez les patients en échec thérapeutique | Veille Pharma | Scoop.it

En dix ans, la mise au point de nouveaux traitements antirétroviraux a amélioré l’état de santé de porteurs du VIH, jusqu’alors en échec thérapeutique vis-à-vis des classes historiques de médicaments.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Cumulative Viral Load Predicts Mortality for Untreated People with HIV

Cumulative Viral Load Predicts Mortality for Untreated People with HIV | Veille Pharma | Scoop.it

"Viremia copy-years," or cumulative HIV viral load over time, was a good predictor of deaths due to all causes among people on combination antiretroviral therapy (ART), independent of cross-sectional, or one-time, viral load measurements or CD4 T-cell counts, researchers reported in the September 2, 2011, advance online edition of Clinical Infectious Diseases.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Changes In Brain Function In Early HIV Infection, A Reliable Indicator Of Disease Prognosis?

Changes In Brain Function In Early HIV Infection, A Reliable Indicator Of Disease Prognosis? | Veille Pharma | Scoop.it

Measurable changes in brain function and communication between brain regions may be a consequence of virus-induced injury during the early stages of human immunodeficiency virus (HIV) infection.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Oral Supervised HIV Self-testing In Malawi Is Acceptable And Accurate

Oral Supervised HIV Self-testing In Malawi Is Acceptable And Accurate | Veille Pharma | Scoop.it

In this week's PLoS Medicine, Augustine Choko of the Malawi-Liverpool Wellcome Trust Clinical Research Programme, Malawi and colleagues assess the uptake and accuracy of home-based supervised oral HIV self-testing in Malawi, demonstrating the feasibility of this approach in a high-prevalence, low-income setting. Their findings indicate that there is strong community readiness to adopt self-testing alongside other HIV counseling and testing strategies in high HIV prevalence settings in urban Africa.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

New Study Adds Guidance On When To Start Antiretroviral Therapy For HIV

New Study Adds Guidance On When To Start Antiretroviral Therapy For HIV | Veille Pharma | Scoop.it

One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ICAAC: Maraviroc May Reduce Liver Fibrosis in HIV/HCV Coinfected People

ICAAC: Maraviroc May Reduce Liver Fibrosis in HIV/HCV Coinfected People | Veille Pharma | Scoop.it

Adding the CCR5 blocker maraviroc (Selzentry) to an antiretroviral regimen reduced liver stiffness, an indicator of fibrosis, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in Chicago.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Case Reports: Cushing\'s Syndrome With Atazanavir/Ritonavir

Case Reports: Cushing\'s Syndrome With Atazanavir/Ritonavir | Veille Pharma | Scoop.it

Two cases have been reported recently of patients developing Cushing's syndrome when treated with atazanavir/ritonavir and corticosteroids.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Early HIV Antiretroviral Therapy Cost-Effective

Early HIV Antiretroviral Therapy Cost-Effective | Veille Pharma | Scoop.it

n the most recent edition of PLoS Medicine, findings of a study conducted by researchers at the Weill Cornell Medical College and GHESKIO (Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes) proves that early treatment of HIV is not only life saving but also cost-effective.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more clinically relevant HIV-related posters (from a U.S. clinician's standpoint) presented at ICAAC 2011 on Sunday, Sept. 18. The order of these summaries is based on poster number, not the importance of the findings.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Ibalizumab Study Casts a Ray of Hope for HIV-Positive People With Extensive Drug Resistance

As the number of first-line HIV treatment options has greatly expanded over the last several years, research on the other end of the spectrum -- on antiretrovirals for people with extensive drug resistance -- has felt more stagnant. Last year's demise of vicriviroc cast a shadow over drug development in "deep salvage" situations, and left many in the field concerned that the small-but-growing number of people with dwindling treatment options may increasingly be up the creek without a paddle.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Initiation of ART During Breastfeeding Can Induce Multidrug Resistance in Infants

In resource-limited settings some HIV-positive women initiate ART during breastfeeding. This exposes infected infants to the risk emergence of resistance to the antiretrovirals in their mothers' regimen.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Once-daily etravirine does well in patients starting HIV therapy

First-line HIV therapy that includes a once-daily dose of the new NNRTI etravirine is just as likely to suppress viral load to undetectable levels as treatment based on efavirenz, a study published in the online edition of AIDS shows.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Elevated Triglycerides and Waist Circumference Predict Cardiovascular Risk for People with HIV

Elevated Triglycerides and Waist Circumference Predict Cardiovascular Risk for People with HIV | Veille Pharma | Scoop.it

HIV positive people with high triglyceride levels and large girth were more likely to have other risk factors associated with cardiovascular disease and events such heart attacks, suggesting that these 2 simple measures may be used to distinguish high-risk versus low-risk individuals, according to a study in the September 22, 2011, edition of the open access journal PLoS ONE.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study

InterpretationA substantial improvement in viral load suppression and accompanying decrease in the rates of AIDS in people after extensive failure to drugs from the three original antiretroviral classes during 2000—09 was probably mainly driven by availability of newer drugs with better tolerability and ease of use and small cross-resistance profiles, suggesting the public health benefit of the introduction of new drugs.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Distinct AIDS Viruses Found In Cerebrospinal Fluid Of People With HIV Dementia

Distinct AIDS Viruses Found In Cerebrospinal Fluid Of People With HIV Dementia | Veille Pharma | Scoop.it

When the virus that causes AIDS infects the central nervous system, it can lead to the development of a severe neurological disease called HIV- associated dementia (HAD).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Keeping HIV Patients on ART Will Have Long-Term Economic Benefits Study Shows

Keeping HIV Patients on ART Will Have Long-Term Economic Benefits Study Shows | Veille Pharma | Scoop.it

Investments to keep 3.5 million people living with HIV on antiretroviral drugs provided by programs co-financed through the Global Fund to Fight AIDS, Tuberculosis and Malaria through 2020 will cost an estimated $14.2 billion, but "the financial savings would amount to between $12 billion and $34 billion," according to a study published in the journal PLoS One, Sarah Boseley reports in her "Global Health Blog" in the Guardian (10/5).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pregnancy & HIV MTCT

HIV positive mothers who use a lopinavir/ritonavir (Kaletra or Alluvia) antiretroviral regimen can reduce the risk of transmitting the virus to their infants during extended supplemental breastfeeding, supporting recent World Health organization (WHO) guidelines.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

New Targets For The Control Of HIV Predicted

New Targets For The Control Of HIV Predicted | Veille Pharma | Scoop.it

A new computational approach has predicted numerous human proteins that the human immunodeficiency virus (HIV) requires to replicate itself. These discoveries "constitute a powerful resource for experimentalists who desire to discover new targets for human proteins that can control the spread of HIV," according to the authors of this study that appears in the Sept. 22, 2011 issue of PLoS Computational Biology, a journal published by the Public Library of Science.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA Approval of Generic ARVs

FDA Approval of Generic ARVs | Veille Pharma | Scoop.it

Since the last issue of HTB, the U.S. Food and Drug Administration (FDA) has granted tentative approval (or full approval*) for the following new generic ARV products.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ICAAC: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV

ICAAC: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV | Veille Pharma | Scoop.it

The HIV integrase inhibitor raltegravir (Isentress) works well for both men and women and people of diverse racial/ethnic groups, according to data from the REALMRK trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

HIV & AIDS Information :: A fifth of patients discontinue Atripla within a year, CNS side-effects the main reason

A fifth of patients who start antiretroviral therapy with Atripla switch to an alternative regimen within a year, according to UK data presented to the 51st ICAAC in Chicago. The main reason for changing therapy was central nervous system side-effects.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Guidelines for treating HIV-infected pregnant women and interventions to prevent perinatal transmission, including information on drug regimens, safety and toxicity of medications, delivery options, and care of infants born to HIV-infected mothers.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

VIH-SIDA : Vacc-4x, l’espoir de pouvoir suspendre sa thérapie antirétrovirale

VIH-SIDA : Vacc-4x, l’espoir de pouvoir suspendre sa thérapie antirétrovirale | Veille Pharma | Scoop.it

Cet essai de phase IIb contrôlé contre placebo, présenté lors de la la Global HIV Vaccine Enterprise de Bankok, le 13 septembre, conclut à l’efficacité et à l’innocuité de Vacc-4x, un vaccin thérapeutique candidat pour traiter les personnes vivant avec le VIH-sida qui suspendent leur thérapie antirétrovirale (TARV). C’est à la fois, une nouvelle approche pour le traitement du VIH et l’espoir d’une stratégie pour réduire la transmission du virus.

more...
No comment yet.